Headlines Eye Drop Company Raises $20M from Novartis, Other Investors Published 3 years ago on January 11, 2018 By INVISION Staff Share Tweet The firm is working on a treatment for diabetic macular edema. LAUSANNE, SWITZERLAND — Oculis, a biotechnology company focused on eye drops, has closed a $20.3 million funding round that included Novartis Venture Fund. The financing was led by a syndicate including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors, including Brunnur Ventures and Silfurberg, also participated in the financing. The funding will be used to advance clinical development of a topical product for treatment of diabetic macular edema. It will also help the company advance the product for other ophthalmic indications and to develop other drug candidates. Endpoints News reports that the goal is “eventually snag a chunk of the market that drugs like Eylea and Lucentis have failed to capture.” Those drugs are given as injections.eventually snag a chunk of the market that drugs like Eylea and Lucentis have failed to capture. Advertisement In conjunction with the financing, Oculis is relocating its corporate headquarters to Lausanne, Switzerland, while its R&D remains in Reykjavik, Iceland. Dr. Riad Sherif, formerly area president for Europe, Middle East and Africa at Alcon and formerly a senior executive at Novartis, has been appointed as CEO of Oculis. “I am extremely pleased to be joining such a great team to develop what could be the next generation of ophthalmic treatments,” Sherif said. “Oculis founders have meticulously developed the novel SNP technology that improves both the ability to formulate drugs as eye drops and their bioavailability in eye tissues including the posterior segment. This technology opens a new era of breakthrough ophthalmic therapies that could provide important benefits to patients. Our goal with the lead program OC-118 is truly to transform the way DME is treated and managed today.” Páll Ragnar Jóhannesson has been named chief financial officer and managing director of Oculis in Iceland. Dr. Sabri Markabi, previously senior vice president, head of R&D and chief medical officer at Alcon, will join as chief scientific officer. The company’s founders, professors Einar Stefánsson and Thorsteinn Loftsson, are taking on the roles of chief innovation officer and chief research and technology officer, respectively. Stefánsson said: “We are transforming eye drop technology and improving drug delivery to all parts of the eye. Treating retinal diseases with eye drops instead of injecting the eye with a needle provides comfortable and accessible treatment options for potentially tens of millions of patients with retinal disease.” Advertisement Florent Gros of Novartis Venture Fund is joining the board as chairman, in addition to Arni Blöndal (Brunnur Ventures) and Stefan J. Sveinsson (formerly Global EVP RD at Actavis), Lionel Carnot (Bay City Capital) and Rob Hopfner (Pivotal Bioventure Partners). Related Topics:diabeteseye healthNovartisOculisresearchtechnology click to Comment(Comment) Up Next Optical Tech Firm Opens US Headquarters Don't Miss Arch Crown Releases New Catalog Advertisement SPONSORED VIDEO SPONSORED BY ESSILOR Introducing EssilorLuxottica 360 A new program powered by Essilor, Luxottica and EyeMed that is designed to help your practice improve traffic, visibility and patient experience while maximizing profitability. Learn More at 360.EssilorLuxottica.com You may like Biomarker Indicating Neurodegeneration Identified in the Eye VSP Vision Care and Livongo Data Sharing Partnership Reduces Gaps in Eye Care for Those Living with Diabetes Why It’s More Important Than Ever to Discuss Blue Light Protection with Patients Promoted Headlines Introducing EssilorLuxottica 360 Essilor American Eyes 2020 — Safilo’s Celebration of U.S. Eye Care Professionals Continues Safilo Introducing C Life by Champion L'Amy Advertisement Latest Trending Videos John Marvin16 hours ago Being Civic-Minded Is Important, but So Is Not Alienating People Press Releases16 hours ago National Leadership Team Development Series Continues Online Tonight The Big survey2 days ago Early Polling in INVISION’s Big Survey Puts One Presidential Nominee On Top By a Narrow Margin Headlines2 days ago FDA Approves Kala’s Eysuvis for Dry Eye Press Releases2 days ago Inspecs and O’Neill Announce License Deal Photo Gallery3 weeks ago Washington Eye Doc Welcomes Autumn … and More Brain Squad Members in Their INVISION T-Shirts Headlines1 week ago Video: Car Crashes Into Optometry Office; 4 Taken to Hospital Photo Gallery1 week ago You Need to See These 28 Head-Turning Ways to Display Frames Headlines3 weeks ago Rocky Mountain University of Health Professions Plans Optometry College Best of the Best3 weeks ago No Qualified Opticians? No Problem. This Oregon Optical Owner Took Matters Into His Own Hands Headlines1 week ago Video: Car Crashes Into Optometry Office; 4 Taken to Hospital Sponsored Content2 months ago Introducing EssilorLuxottica 360 Sponsored Webinars2 months ago Introducing Varilux® Comfort Max Lenses Headlines2 months ago Video: Gandhi’s Eyeglasses Could Fetch $19K+ at Auction INVISION Podcast3 months ago Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop Advertisement SubscribeBULLETINS Get the most important news and business ideas for eyecare professionals every weekday from INVISION. Advertisement Most Popular Headlines1 week ago Video: Car Crashes Into Optometry Office; 4 Taken to Hospital Photo Gallery1 week ago You Need to See These 28 Head-Turning Ways to Display Frames Press Releases1 week ago BVI Acquires Benz Research & Development The Big survey2 days ago Early Polling in INVISION’s Big Survey Puts One Presidential Nominee On Top By a Narrow Margin Press Releases16 hours ago National Leadership Team Development Series Continues Online Tonight Headlines4 days ago Co-Founder of National Optometric Association Dies at 93 Headlines2 days ago FDA Approves Kala’s Eysuvis for Dry Eye Cover Stories3 days ago Is Corporate Optometry the Future of Optometry?